Literature DB >> 7485397

Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton.

M A den Bakker1, M Tascilar, P H Riegman, A C Hekman, W Boersma, P J Janssen, T A de Jong, W Hendriks, T H van der Kwast, E C Zwarthoff.   

Abstract

The product of the neurofibromatosis type 2 (NF2) tumor suppressor gene is a 595-amino-acid protein bearing resemblance to a family of band-4.1-related proteins. These proteins, including ezrin, radixin, and moesin, probably function as molecular linking proteins, connecting the cytoskeleton to the cell membrane. On the grounds of the homology to the ezrin, radixin, and moesin proteins and on the basis of its predicted secondary structure, the NF2 protein is also thought to act as a cytoskeleton-cell membrane linking protein. Using monoclonal antibodies to amino- and carboxyl-terminal synthetic NF2 peptides we demonstrate the co-localization of the NF2 protein with elements of the cytoskeleton in a COS cell model system and in cultured human cells. Furthermore, the presence of the NF2 protein in tissue sections is shown. The monoclonal antibodies specifically stain smooth muscle cells and the stratum granulosum of the human epidermis. In cultured smooth muscle cells the NF2 protein co-localizes with actin stress fibers. Immunoelectron microscopy demonstrates the presence of the NF2 protein associated with keratohyalin granules and to a lesser extent with intermediate filaments in the human epidermis. We conclude that the NF2 protein is indeed associated with multiple elements of the cytoskeleton.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485397      PMCID: PMC1869530     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

Review 1.  NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update.

Authors:  J J Mulvihill; D M Parry; J L Sherman; A Pikus; M I Kaiser-Kupfer; R Eldridge
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

2.  The dot immunobinding assay.

Authors:  R Hawkes
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy.

Authors:  N D Zegers; E Claassen; C Neelen; E Mulder; J H van Laar; M M Voorhorst; C A Berrevoets; A O Brinkmann; T H van der Kwast; J A Ruizeveld de Winter
Journal:  Biochim Biophys Acta       Date:  1991-01-23

4.  The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2.

Authors:  M I Kaiser-Kupfer; V Freidlin; M B Datiles; P A Edwards; J L Sherman; D Parry; L M McCain; R Eldridge
Journal:  Arch Ophthalmol       Date:  1989-04

5.  Presence and localization of proteins immunologically related to erythrocyte protein 4.1 in human skin.

Authors:  T Shimizu; Y Takakuwa; H Koizumi; T Ishibashi; A Ohkawara
Journal:  Histochemistry       Date:  1991

Review 6.  Neurofibromatosis 2 (bilateral acoustic neurofibromatosis).

Authors:  R L Martuza; R Eldridge
Journal:  N Engl J Med       Date:  1988-03-17       Impact factor: 91.245

7.  Lysosomal localization of secretory prostatic acid phosphatase in human hyperplastic prostate epithelium.

Authors:  P E Zondervan; T H van der Kwast; A de Jong; W J Visser; W C de Bruijn
Journal:  Urol Res       Date:  1986

8.  Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity.

Authors:  D M Parry; R Eldridge; M I Kaiser-Kupfer; E A Bouzas; A Pikus; N Patronas
Journal:  Am J Med Genet       Date:  1994-10-01

9.  Microtubules containing detyrosinated tubulin are less dynamic.

Authors:  T E Kreis
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

10.  Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA.

Authors:  J L Rodríguez Fernández; B Geiger; D Salomon; I Sabanay; M Zöller; A Ben-Ze'ev
Journal:  J Cell Biol       Date:  1992-10       Impact factor: 10.539

View more
  5 in total

1.  Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.

Authors:  Minja Laulajainen; Taru Muranen; Tuula A Nyman; Olli Carpén; Mikaela Grönholm
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

2.  Characterization of human palladin, a microfilament-associated protein.

Authors:  O M Mykkänen; M Grönholm; M Rönty; M Lalowski; P Salmikangas; H Suila; O Carpén
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

3.  Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

Authors:  R P Stokowski; D R Cox
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

4.  Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins.

Authors:  L Goutebroze; E Brault; C Muchardt; J Camonis; G Thomas
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

5.  Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity.

Authors:  Minja Laulajainen; Maria Melikova; Taru Muranen; Olli Carpén; Mikaela Grönholm
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.